Trial Profile
An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Niacin/laropiprant (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 09 Dec 2009 Patient numbers amended from 160 to 188 as reported by ClinicalTrials.gov.
- 29 Jul 2009 New trial record